Company Update (NASDAQ:PTX): Pernix Therapeutics Holdings Inc Appoints New Member to Board of Directors

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced the appointment of Gabriel Leung to its Board of Directors, effective immediately. The Board also determined that Mr. Leung is an independent director and appointed him as chairperson of the Nominating Committee and as a member of the Audit and Compensation Committees.

“I’m very pleased to welcome Mr. Leung to the Board,” said John Sedor, Chairman and Chief Executive Officer. “His strong background in pharmaceutical business and strategy, industry relationships and established track record of helping to increase shareholder value will be invaluable to Pernix and its shareholders.”

Mr. Leung is currently Vice Chairman and Board member of NovoCure Limited, a publicly listed commercial-stage oncology company developing a novel, proprietary therapy called TTFields for the treatment of solid tumor cancers.  He was most recently Executive Vice President of OSI Pharmaceuticals, Inc. and President of OSI’s Oncology and Diabetes Business, from 2003 to 2010, prior to its acquisition by Astellas Pharma Inc. Mr. Leung was responsible for the launch of erlotinib (Tarceva) at OSI. Prior to his tenure at OSI, from 1999 to 2003, Mr. Leung served as Group Vice President of the global prescription business at Pharmacia Corporation, a global pharmaceutical and healthcare company, leading Pharmacia’s global oncology franchise in over 80 countries. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company, where he was responsible for the growth of Taxol and Paraplatin. In addition, Mr. Leung served as a director for Albany Molecular Research Inc. (AMRI), a global contract research and manufacturing company, from 2010 to 2016 and as a director of Delcath Systems, Inc. from 2011 to 2014, a specialty pharmaceutical and medical device company.

Mr. Leung earned his B.S. in Pharmacy with high honors at the University of Texas at Austin. Mr. Leung attended graduate school at the University of Wisconsin-Madison, where he earned his M.S. in Pharmacy, with a concentration in pharmaceutical marketing. (Original Source)

Shares of Pernix Therapeutics are currently trading at $3.54, up 0.02 or +0.57%. PTX has a 1-year high of $31.20 and a 1-year low of $3.11. The stock’s 50-day moving average is $5.14 and its 200-day moving average is $5.58.

On the ratings front, Aegis Capital Corp. analyst Difei Yang downgraded PTX to Hold, in a report issued on August 12. According to, Yang has a yearly average return of 0.7%, a 44% success rate, and is ranked #1891 out of 4235 analysts.

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla. 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts